Targets › GAD1
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Oct 2029.
Catalyzes the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) with pyridoxal 5'-phosphate as cofactor..; FUNCTION: [Isoform 3]: Enzymatically inactive as glutamate decarboxylase. (UniProt, Q99259)
Open in Phaseline: the race on GAD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MeiraGTx | AAV-GAD Glutamic acid decarboxylase (GAD) gene transfer via adeno-associated virus | GAD1 | Phase 1 | Parkinson's Disease | Oct 2029 |
Parkinson's Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.